How is the Arbutus Biopharma Corp today?

The Arbutus Biopharma Corp today is trading in the green, up by 0.30% at 3.38.

How has Arbutus Biopharma Corp performed historically?

The Arbutus Biopharma Corp is currently trading up 0.30% on an intraday basis in the past week the index fell -2.03%. The index has been down -0.29% in the past quarter and rose 10.10% in the past year. You can view this in the overview section.

What is Arbutus Biopharma Corp Annual Revenue?

Arbutus Biopharma Corp Annual Revenue fell 65.98%, in the last year to $6.17 M. Its sector's average revenue growth for the last fiscal year was 8.76%.

What is Arbutus Biopharma Corp Annual Net Profit?

Arbutus Biopharma Corp Annual Net Profit rose 4.02% in the last year to $69.92 M. Its sector's average net profit growth for the last fiscal year was -14.06%.

What is Arbutus Biopharma Corp Price to Earning Ratio?

Arbutus Biopharma Corp Price to Earning Ratio is -8.45, which is negative.

What is Arbutus Biopharma Corp Stock Price?

Arbutus Biopharma Corp Stock Price rose 10.1% and underperformed its sector by 31.87% in the past year.

What is Arbutus Biopharma Corp Quarterly Revenue?

Arbutus Biopharma Corp Quarterly Revenue rose 15.14% YoY to $1.76 M. Its sector's average revenue growth YoY for the quarter was 3.14%.

What is Arbutus Biopharma Corp Quarterly Net profit?

Arbutus Biopharma Corp Quarterly Net profit fell 37.21% YoY to $24.53 M. Its sector's average net profit growth YoY for the quarter was -236.04%.

What is Arbutus Biopharma Corp Debt to Equity Ratio?

Arbutus Biopharma Corp Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Arbutus Biopharma Corp Return on Equity(ROE)?

Arbutus Biopharma Corp Return on Equity(ROE) for the last financial year was -68.76%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Arbutus Biopharma Corp Mutual Fund Holding?

Arbutus Biopharma Corp Mutual Fund Holding decreased by 0.22% in the last quarter to 30.47.

What is Arbutus Biopharma Corp Interest Coverage Ratio?

Arbutus Biopharma Corp Interest Coverage Ratio is -509.36, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Arbutus Biopharma Corp Institutional Holding?

Arbutus Biopharma Corp Institutional Holding increased by 4.71% in the last quarter to 58.16.

MARKETS
SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
INDUSTRY : MAJOR PHARMACEUTICALS
ARBUTUS BIOPHARMA CORP

Arbutus Biopharma Corp XNAS: ABUS

Arbutus Biopharma Corp Live Share Price Today, Share Analysis and Chart

Name: Arbutus Biopharma Corp: Is Infosys Ltd. worth buying?
Item: Arbutus Biopharma Corp
Rating: 1.27458325
Author: Trendlyne DVM scores

about

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can b...

3.38 0.01 (0.30%)

28.39% Fall from 52W High

233.7K

XNAS Volume

XNAS 25 Jun, 2025 2:15 PM (EDT)

Not Eligible

Expensive Valuation

4.8 / 100

Technically Neutral

46.2 / 100

1Yr Price target upside is 59%

4 analysts

Arbutus Biopharma Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Arbutus Biopharma Corp Live Share Price Today, Share Analysis and Chart

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can b...

28.39% Fall from 52W High

SWOT Analysis

Arbutus Biopharma Corp Live Price Chart

Arbutus Biopharma Corp FAQ

How is Arbutus Biopharma Corp today?

Arbutus Biopharma Corp today is trading in the green, and is up by 0.30% at 3.38.

How has Arbutus Biopharma Corp performed historically?

Arbutus Biopharma Corp is currently trading up 0.30% on an intraday basis. In the past week the stock fell -2.03%. stock has been down -0.29% in the past quarter and rose 10.10% in the past year. You can view this in the overview section.